Loading search results
CEDRN OUD
Optimizing Outcomes for Patients Presenting to Emergency Departments With Opioid Poisoning
Sponsor study identifier
Secondary identifiers
OTHER_GRANT · Canadian Institutes of Health Research (CIHR)
observational
7,200
1 country
1
Study Start
July 24, 2025
Actual (reported)Primary Completion
July 24, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Unregulated opioids remain a leading driver of preventable mortality and potential years of life lost in Canada. Emergency departments (EDs)-open 24/7 and frequently accessed by people who use drugs-offer critical opportunities to reverse toxicity, mitigate harm, and initiate treatment. Yet, high quality evidence to guide ED care for patients with opioid poisoning and concomitant opioid dependence or opioid use disorder is limited. The investigators aim to establish a pan Canadian registry of patients presenting to EDs with opioid poisoning to generate timely, practice informing evidence. The investigators will create the Canadian Emergency Department Research Network (CEDRN) Opioid Registry across participating EDs nationwide. Using automated screening of electronic health records (EHRs), the investigators will identify consecutive patients of all ages with suspected or confirmed opioid poisoning at their index ED visit. The project's objectives are to establish a pan-Canadian registry of Emergency Department patients presenting with opioid poisoning, harmonize data collection across participating sites, describe variations in patient characteristics, clinical practice and outcomes, and derive a clinical decision rule to predict the risk of dying within 60 days. The expected outcomes include advancing healthcare delivery, improving patient and provider experiences, and enhancing population health and health system sustainability for individuals with opioid poisoning. This research is crucial for addressing the opioid crisis in Canada and has the potential to significantly impact patient care and outcomes.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 24, 2025
Actual (reported)February 20, 2026
Actual (reported)March 12, 2026
Actual (reported)July 24, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Proportion of patients who received opioid agonist therapy (methadone, buprenorphine/naloxone, extended release buprenorphine injection, slow-release oral morphine).
Number of patients that were administered any of the following types of opioid agonist therapy during their visit to the emergency department.
From date of emergency department arrival date until they are discharged from the emergency department (usually within the first 72 hours since arrival time).
Proportion of patients who left against medical advice.
From date of emergency department arrival date until date and time of first documented "leaving against medical advice" or "leaving without being seen" or other similar terms in patient's medical chart (within the first 72 hours since arrival).
All patients presenting to any one of the Canadian Emergency Department Research Network's emergency department, and meeting the inclusion criteria.
Vancouver General Hospital
Vancouver, British Columbia, V5Z 1M9, Canada
Kaczorowski J, Bilodeau J, M Orkin A, Dong K, Daoust R, Kestler A. Emergency Department-initiated Interventions for Patients With Opioid Use Disorder: A Systematic Review. Acad Emerg Med. 2020 Nov;27(11):1173-1182. doi: 10.1111/acem.14054. Epub 2020 Jul 28.
Chen Y, Wang Y, Nielsen S, Kuhn L, Lam T. A systematic review of opioid overdose interventions delivered within emergency departments. Drug Alcohol Depend. 2020 Aug 1;213:108009. doi: 10.1016/j.drugalcdep.2020.108009. Epub 2020 May 23.
Corinne M Hohl, MD, MPH
University of British Columbia
First Submitted
February 20, 2026
First Posted
March 12, 2026
Study Start
July 24, 2025
Actual (reported)Primary Completion
July 24, 2030
EstimatedProportion of patients hospitalized
From date of emergency department arrival date until they are discharged from the emergency department (usually within the first 72 hours since arrival time).
Proportion of naloxone administration
From date of emergency department arrival date until they are discharged from the emergency department (usually within the first 72 hours since arrival time).
Contact the study team to confirm eligibility.
D'Onofrio G, O'Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, Bernstein SL, Fiellin DA. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015 Apr 28;313(16):1636-44. doi: 10.1001/jama.2015.3474.
Moe J, Badke K, Pratt M, Cho RY, Azar P, Flemming H, Sutherland KA, Harvey B, Gurney L, Lockington J, Brasher P, Gill S, Garrod E, Bath M, Kestler A. Microdosing and standard-dosing take-home buprenorphine from the emergency department: A feasibility study. J Am Coll Emerg Physicians Open. 2020 Oct 20;1(6):1712-1722. doi: 10.1002/emp2.12289. eCollection 2020 Dec.
Moe J, Chong M, Zhao B, Scheuermeyer FX, Purssell R, Slaunwhite A. Death after emergency department visits for opioid overdose in British Columbia: a retrospective cohort analysis. CMAJ Open. 2021 Mar 17;9(1):E242-E251. doi: 10.9778/cmajo.20200169. Print 2021 Jan-Mar.
Zhang X, Wang N, Hou F, Ali Y, Dora-Laskey A, Dahlem CH, McCabe SE. Emergency Department Visits by Patients with Substance Use Disorder in the United States. West J Emerg Med. 2021 Aug 19;22(5):1076-1085. doi: 10.5811/westjem.2021.3.50839.
Beckerleg W, Hudgins J. Substance Use-related Emergency Department Visits and Resource Utilization. West J Emerg Med. 2022 Feb 28;23(2):166-173. doi: 10.5811/westjem.2022.1.53834.
Mok V, Brebner C, Yap J, Asamoah-Boaheng M, Hutton J, Haines M, Scheuermeyer F, Kawano T, Christenson J, Grunau B. Non-prescription drug-associated out-of-hospital cardiac arrest: Changes in incidence over time and the odds of receiving resuscitation. Resuscitation. 2024 Feb;195:110107. doi: 10.1016/j.resuscitation.2023.110107. Epub 2023 Dec 30.
Hawk K, Hoppe J, Ketcham E, LaPietra A, Moulin A, Nelson L, Schwarz E, Shahid S, Stader D, Wilson MP, D'Onofrio G. Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department. Ann Emerg Med. 2021 Sep;78(3):434-442. doi: 10.1016/j.annemergmed.2021.04.023. Epub 2021 Jun 23.
Gomes T, Kitchen SA, Murray R. Measuring the Burden of Opioid-Related Mortality in Ontario, Canada, During the COVID-19 Pandemic. JAMA Netw Open. 2021 May 3;4(5):e2112865. doi: 10.1001/jamanetworkopen.2021.12865.
Gomes T, Campbell TJ, Kitchen SA, Garg R, Bozinoff N, Men S, Tadrous M, Munro C, Antoniou T, Werb D, Wyman J. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation. JAMA. 2022 Mar 1;327(9):846-855. doi: 10.1001/jama.2022.1271.
Fischer B. The continuous opioid death crisis in Canada: changing characteristics and implications for path options forward. Lancet Reg Health Am. 2023 Feb 3;19:100437. doi: 10.1016/j.lana.2023.100437. eCollection 2023 Mar. No abstract available.
Nguyen T, Buxton JA. Pathways between COVID-19 public health responses and increasing overdose risks: A rapid review and conceptual framework. Int J Drug Policy. 2021 Jul;93:103236. doi: 10.1016/j.drugpo.2021.103236. Epub 2021 Mar 20.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
March 12, 2026
Record last verified: 2026-03
Data is only available for CEDRN members. Non-member researchers interested in using any CEDRN data must be voted in by the CEDRN Executive Committee. For more information, please inquire https://cedrn.ca/collaborate/
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: